Strategic Appointment to Expand Global Markets

Drug discovery software developer Optibrium has appointed Dr Tim Hohm as Director of Commercial Strategy and Business Development with a focus on expanding its global customer base. His role will also involve market and customer insight in relation to the Company’s StarDrop™ and Augmented Chemistry™ products and services, helping to guide the continued development of the company’s in silico drug discovery technologies and artificial intelligence services.

Tim joins Optibrium from Novo Nordisk, where as Senior Competitive Intelligence Manager he was responsible for digital health and delivery technology with responsibilities including strategy development, defining target product profiles and building business cases for pipeline projects and external opportunities. Tim has a PhD in Computational Biology from ETH Zurich and research experience with optimisation heuristics and quantitative modelling of gene regulatory networks. He also obtained an MBA from the internationally recognised Copenhagen Business School.

Dr Matthew Segall, Optibrium’s CEO, said: “Tim’s background in business strategy, and combined experience in the drug development value chain, pharmaceutical research and development and computational sciences, will be invaluable in attaining our ambitious expansion plans and sustained commercial growth. We are delighted to welcome Tim to our senior team and look forward to him developing Optibrium’s global customer base, supporting our objectives to extend and enhance our innovative drug discovery software and services.”